Todd ShriberInvestorPlace Contributor
Join Louis Navellier’s Market 360 — FREE!
Get Louis Navellier’s take on the news and events impacting the market, plus advice on the best stocks to buy & sell now.
The Dow notched its biggest advance in more than a week Monday, but investors should beware getting carried away. Yes, these gains are important, but remember that this week could be the worst in terms of COVID-19 fatalities.
Even with the sense of urgency surrounding coronavirus treatments, developers need to worth their way through the regulatory process, one that dictates it could be a year or more before a COVID-19 vaccine, such as Moderna's mRNA-1273, could be made available to patients. As such, it could be another couple of months before the company's Phase 1 data is made public.
With S&P 500 dividends under duress this year, investors should focus on quality dividend aristocrat ETFs that offer impressive growth.
Norwegian is facing an extended zero-revenue climate, so it's unlikely NCLH stock will truly thrive until cruise demand returns to normal.
March jobs data was bad, indicating the April and May reports could be worse, putting pressure on stocks to close the week.